The DOI matches its Crossref record.
Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group.
Abstract
PURPOSE: In 1984, the German Breast Cancer Study Group (GBSG) started a multicenter randomized clinical trial to compare the effectiveness of three versus six cycles of 500 mg/m2 cyclophosphamide, 40 mg/m2 methotrexate, and 600 mg/m2 fluorouracil (CMF) on day 1 and 8 starting perioperatively with or without tamoxifen (TAM) (3 x 10 mg/d for 2 years). The aim of the trial was to compare recurrence-free and overall survival between the different treatment modalities. PATIENTS AND METHODS: During 5 years, 41 institutions randomized 473 patients (3 x CMF: 145; 3 x CMF + TAM: 93; 6 x CMF 144; 6 x CMF + TAM: 91). Until March 31, 1992, median follow-up time was 56 months with 197 events for disease-free survival and 116 deaths observed. This provides a power of approximately 80% to detect a potential treatment difference corresponding to a relative risk (RR) of 0.67 for recurrence-free survival. Treatment modalities and various patient characteristics were evaluated by means of a multivariate Cox regression analysis. RESULTS: No significant difference in recurrence-free survival was observed with respect to hormonal therapy (RR = 0.75 TAM v no TAM; 95% confidence interval [CI], 0.54 to 1.04; P = .08) as well as duration of chemotherapy (RR = 0.90 of 6 x CMF v 3 x CMF; 95% CI, 0.67 to 1.19; P = .45). Similar results were obtained for overall survival. The multivariate analysis revealed a significant prognostic impact of the number of positive lymph nodes and the progesterone receptor level on recurrence-free survival. Compliance with chemotherapy within the range of 85% to 115% of the target dose was achieved in 94% and 78% of the patients randomized to 3 x CMF and 6 x CMF, respectively. Sufficient compliance with TAM was reported for 141 patients (93%). CONCLUSION: At this stage of follow-up, six courses of CMF are not superior to three courses with respect to recurrence-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Katzman, J. L., Shaham, U., Cloninger, A., Bates, J., Jiang, T., & Kluger, Y. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0482-1 · Cited by 1,995
“Next, we calculate the recommender function (Equation 5) for all patients in the GBSG test set and determine the recommended treatment for each patient.”
BackgroundInfluentialPrognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research
Riley, R. D., Hayden, J. A., Steyerberg, E. W., Moons, K. G. M., Abrams, K., Kyzas, P. A., Malats, N., Briggs, A., Schroter, S., Altman, D. G., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001380 · Cited by 823
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Infante, G., Miceli, R., & Ambrogi, F. (2023) · Statistics in Medicine · doi:10.1002/sim.9931 · Cited by 33
Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET)
Shelby, R. A., Dorfman, C. S., Bosworth, H. B., Keefe, F., Sutton, L., Owen, L., Corsino, L., Erkanli, A., Reed, S. D., Arthur, S. S., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.11.010 · Cited by 18
Metadata
- Authors
- Schumacher, M., Bastert, G., Bojar, H., Hübner, K., Olschewski, M., Sauerbrei, W., Schmoor, C., Beyerle, C., Neumann, R. L., & Rauschecker, H. F.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-10
- Volume
- 12
- Issue
- 10
- Pages
- 2086-2093
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2236833089
- Cited by
- 242
- References
- 0
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group. https://app.cochat.ai/papers/10.1200/jco.1994.12.10.2086
- The paper
- Schumacher, M., Bastert, G., Bojar, H., Hübner, K., Olschewski, M., Sauerbrei, W., Schmoor, C., Beyerle, C., Neumann, R. L., & Rauschecker, H. F. (1994). Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.10.2086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.